DT19 c'd PCT/PTO 0 7 JAN 2005

Attorney Docket No.: I-2002.010 US

Customer No.: 31846

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DELBECQ ET AL.

Serial Number: To be assigned

Group Art Unit: To be assigned

Filed: January 7, 2005

Examiner: To be assigned

For: IMMUNOGENIC COMPOSITION

Corresponding to:

PCT/EP03/07477 filed September 7, 2003

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97(b)

Honorable Assistant Commissioner of Patents Alexandria, VA 22313

January 7, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08A and PTO-SB-08B. These references were cited in the parent case a Search Report for the corresponding European application. Copies of the Search Report and cited references are enclosed.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the last of (1) issuance of a first official action on the merits and (2) expiration of the three month period following filing of the above-captioned application.

1

Express Mail: EV 389657496 US

Attorney Docket No.: I-2002.010 US

Customer No.: 31846

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the information be considered during the prosecution of this application and that the cited documents be listed on the front page of any patent issuing from this application.

The Patent Office is authorized to charge our Deposit Account No. 02-2334 for any fee which it deems to be required to effect consideration of this statement.

Respectfully submitted,

William P. Ramey, III
Attorney for Applicants

Registration No.44, 295

Akzo Pharma Patent Department P.O. Box 318 29160 Intervet Lane Millsboro, DE 19966

Tel: (302) 933-4034 Fax: (302) 934-4305

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Panerwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449/PTO	Complete if Known		
	Application Number	To Be Assigned 10 // 5 20 6	
INFORMATION DISCLOSURE	Filing Date	January 7, 2005	
	First Named Inventor	DELBECQ, et al.	
SIBIENIENI EV ADDIN'ANI	4 4 1 1 5	I— —	

NI BY APPL Art Unit To Be Assigned (Use as many sheets as necessary) To Be Assigned **Examiner Name** Attorney Docket Number I-2002.010 US Sheet

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 6,069,230	05-30-2000		
		US-			
		US-	T		
		US-			
-		US-	1.		
		US-			
		US-			
		US-			
		US-			
		US-		•	
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Cite Initials* No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	1
		WO 89/01041	02-09-1989			
						L
		1,000			ļ	L
	<u> </u>					L
	I		1			ı

$\overline{}$		
Examiner	 Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\)Applicant's unique citation designation number (optional). \(^2\)See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \(^3\)Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\)For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\)Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\)Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO	Complete if Known		
	Application Number	To Be Assigned 10/520698	
INFORMATION DISCLOSURE		January 7, 2005	
STATEMENT BY APPLICANT	First Named Inventor	DELBECQ, ET AL.	
(Use as many sheets as necessary)	Art Unit	To Be Assigned	
	Examiner Name	To Be Assigned	
Sheet 1 of 1	Attorney Docket Number	I-2002.010 US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ARMAH, G. et al: "Conformation and immunogenicity of engineered repeating segment of circumsporozoite" Molecular and Biochemcial Parasitology (1990) V38 N1 pp135-140	
		CARCY, B. et al: "A 37-Kilodalton Glycoprotein of Babesia divergens" Infection and Immunity, American Society for Microbiology 03/1995), V63 N3 pp 811-817	
		VOETEN, J.T.M. et al: "Introduction of the haemagglutinin transmembrane region" Vaccine, Butterworth Scientific (10/15/2000) V19 N 4-5, pp 514-522, Guildford, GB	
		,	
	<u>' </u>		<u> </u>

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.